Rhythm Pharmaceuticals's three largest insider shareholders as of June 18, 2026 are David P Meeker (President And Ceo, 239.02K shares), Hunter C Smith (Chief Financial Officer, 116.61K shares), Yann Mazabraud (Evp, Head Of International, 66.03K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| David W J Mcgirr | - | 7,000 | 0 | 23 Jun, 2025 |
| Jennifer L Good | - | 7,000 | 0 | 23 Jun, 2025 |
| Christopher Paul German | Corporate Controller Cao | 160 | 0 | 06 Mar, 2026 |
| Camille L Bedrosian | - | 7,000 | 0 | 23 Jun, 2025 |
| Edward T Mathers | - | 0 | 14,168 | 16 Mar, 2026 |
| Christophe Jean | - | 7,000 | 0 | 23 Jun, 2025 |
| David P Meeker | President And Ceo | 239,016 | 0 | 03 Feb, 2026 |
| Stuart A Arbuckle | - | 7,000 | 0 | 23 Jun, 2025 |
| Hunter C Smith | Chief Financial Officer | 116,611 | 0 | 02 Mar, 2026 |
| Lynn A. Tetrault | - | 7,000 | 0 | 23 Jun, 2025 |
| Yann Mazabraud | Evp, Head Of International | 66,030 | 0 | 03 Apr, 2026 |
| Jennifer Kayden Lee | Evp, Head Of North America | 19,233 | 0 | 03 Feb, 2026 |
| William T. Roberts | Chief Accounting Officer | 7,872 | 0 | 31 Mar, 2023 |
| Pamela J. Cramer | Chief Human Resources Officer | 29,376 | 0 | 03 Feb, 2026 |
| Joseph Shulman | Chief Technical Officer | 18,970 | 0 | 03 Feb, 2026 |
| Alastair Garfield | Chief Scientific Officer | 7,763 | 0 | 03 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Yann Mazabraud | Common Stock | A | 12,875 | - | 66,030 | D | M |
| 01 Apr, 2026 | Kimberly J Popovits | Restricted Stock Units | A | 6,808 | $0.00 | 6,808 | D | A |
| 01 Apr, 2026 | Yann Mazabraud | Restricted Stock Units | D | 10,375 | $0.00 | 10,375 | D | M |
| 01 Apr, 2026 | Kimberly J Popovits | Stock Options (Right to Buy) | A | 10,257 | $0.00 | 10,257 | D | A |
| 01 Apr, 2026 | Yann Mazabraud | Restricted Stock Units | D | 2,500 | $0.00 | 5,000 | D | M |
| 12 Mar, 2026 | Edward T Mathers | Common Stock | A | 4,199 | $0.00 | 14,168 | I | J |
| 04 Mar, 2026 | Christopher Paul German | Common Stock | A | 1,500 | $17.97 | 5,753 | D | M |
| 04 Mar, 2026 | Christopher Paul German | Common Stock | D | 5,614 | $89.56 | 160 | D | S |
| 04 Mar, 2026 | Christopher Paul German | Stock Options (Right to Buy) | D | 1,500 | $0.00 | 3,731 | D | M |
| 02 Mar, 2026 | Yann Mazabraud | Stock Options (Right to Buy) | A | 35,000 | $0.00 | 35,000 | D | A |
| 02 Mar, 2026 | Edward T Mathers | Common Stock | A | 4,198 | $0.00 | 9,969 | I | J |
| 01 Mar, 2026 | Christopher Paul German | Common Stock | A | 1,162 | - | 4,595 | D | M |
| 01 Mar, 2026 | Christopher Paul German | Common Stock | D | 342 | $94.94 | 4,253 | D | F |
| 01 Mar, 2026 | Christopher Paul German | Restricted Stock Units | D | 1,162 | $0.00 | 1,162 | D | M |
| 02 Mar, 2026 | Hunter C Smith | Common Stock | A | 6,099 | $6.80 | 116,611 | D | M |
| 02 Mar, 2026 | Hunter C Smith | Common Stock | A | 6,099 | $6.80 | 116,611 | D | M |
| 02 Mar, 2026 | Hunter C Smith | Stock Options (Right to Buy) | D | 6,099 | $0.00 | 91,401 | D | M |
| 02 Mar, 2026 | Hunter C Smith | Stock Options (Right to Buy) | D | 6,099 | $0.00 | 91,401 | D | M |
| 17 Feb, 2026 | Hunter C Smith | Common Stock | D | 1,200 | $99.42 | 117,266 | D | S |
| 17 Feb, 2026 | Hunter C Smith | Common Stock | D | 1,200 | $99.42 | 117,266 | D | S |